Fluoxetine, topiramate, and combination of both to stabilize eating behavior before bariatric surgery.

INTRODUCTION: Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction (reduction in body fat, risk factors for cardiovascular disease and the incidence of diabetes mellitus). Among drugs that have been evaluated for weight loss include antidepressants (fluoxetine) and antiepileptic (topiramate). MATERIAL AND METHODS: We analyzed eating behavior and weight loss in a sample of morbid obesity patients before bariatric surgery. The patients suffering eating disturbances symptoms were grouped into three groups: one group received 40 mg of flouxetine/day (Group A); another group received topiramate 200 mg/day (Group B); and the third group of patients were treated with fluoxetine 40 mg and 200 mg of topiramate/day (Group C). RESULTS: Patients treated with fluoxetine plus topiramate lost more weight at 3 and 6 months before surgery. CONCLUSIONS: The use of the psychopharmaceutical drug (fluoxetine and topiramate) in morbid obese patients with eating disorders could represent a new approach to the management of eating behavior before bariatric surgery.

Fluoxetina, topiramato y combinación de ambos en el control de la conducta alimentaria antes de la cirugía bariátrica / Fluoxetine, topiramate, and combination of both to stabilize eating behavior before bariatric surgery

Introducción. El tratamiento farmacológico de la obesidad está dirigido principalmente a la pérdida de peso, mantenimiento de la pérdida de peso y la reducción del riesgo (reducción de la grasa corporal, factores de riesgo cardiovasculares y la incidencia de diabetes mellitus). Entre los fármacos que han sido evaluados para bajar de peso están los antidepresivos (fluoxetina) y antiepilépticos (topiramato). Material y Métodos. Se analiza la conducta alimentaria y la pérdida de peso en una muestra de pacientes con obesidad mórbida antes de la cirugía bariátrica. Aquellos pacientes que sufrían trastornos alimentarios se agruparon en tres grupos: un grupo recibió 40 mg de fluoxetina/día (Grupo A); topiramato 200 mg/día (Grupo B) y el otro fluoxetina 40 mg y 200 mg de topiramato (Grupo C). Resultados. Los pacientes tratados con fluoxetina más topiramato perdieron más peso a los 3 y 6 meses antes de la cirugía. Conclusiones. El uso de psicofármacos (fluoxetina y topiramato) en pacientes obesos mórbidos con trastornos de la alimentación puede representar una ayuda para el manejo de la conducta alimentaria antes de la cirugía bariátrica

Introduction. Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction (reduction in body fat, risk factors for cardiovascular disease and the incidence of diabetes mellitus). Among drugs that have been evaluated for weight loss include antidepressants (fluoxetine) and antiepileptic (topiramate). Material and Methods. We analyzed eating behavior and weight loss in a sample of morbid obesity patients before bariatric surgery. The patients suffering eating disturbances symptoms were grouped into three groups: one group received 40 mg of flouxetine/day (Group A); another group received topiramate 200 mg/day (Group B); and the third group of patients were treated with fluoxetine 40 mg and 200 mg of topiramate/day (Group C). Results. Patients treated with fluoxetine plus topiramate lost more weight at 3 and 6 months before surgery. Conclusions. The use of the psychopharmaceutical drug (fluoxetine and topiramate) in morbid obese patients with eating disorders could represent a new approach to the management of eating behavior before bariatric surgery

Relación entre tabaco y sintomatología psicótica en paciente tratado con olanzapina oral. A propósito de un caso / Relationship between smoking and psychotic symptoms in a patient treated with oral olanzapine. A case report

No disponible

Concurrencia de múltiples factores en la aparición de arritmia ventricular en paciente en tratamiento con aripiprazol / Concurrence of multiples factors in the ocurrence of ventricular arrhythmia in patient treated with aripiprazole

Introducción. Importancia de los efectos cardiovasculares, fundamentalmente las arritmias ventriculares, producidos por los antipsicóticos. Caso clínico. Paciente de 28 años con obesidad mórbida, por la que fue intervenido obteniendo buenos resultados, sufre una taquicardia ventricular no sostenida polimórfica mientras realizaba tratamiento farmacológico con aripiprazol y fluoxetina. Conclusiones. Valorar la influencia de diversos factores en la producción de arritmias ventriculares, destacando fundamentalmente las interacciones de los antipsicóticos y la pérdida de peso (AU)

Introduction. The Importance of the cardiovascular effects, fundamentally the ventricular arrhythmias, produced by the antipsychotic ones, is discussed. Clinical case. 28 year old patient with morbid obesity, operated by bariatric surgery, with good result, suffers a ventricular no supported polymorphic tachycardia while he was heightening treatment with aripiprazole and fluoxetine. Conclusions. To value the influence of diverse factors for the production of ventricular arrhythmias emphasizing fundamentally the interactions of aripiprazole and the loss of weight (AU)

Concurrence of multiples factors in the occurrence of ventricular arrhythmia in patient treated with aripiprazole.

INTRODUCTION: The Importance of the cardiovascular effects, fundamentally the ventricular arrhythmias, produced by the antipsychotic ones, is discussed. CLINICAL CASE: 28 year old patient with morbid obesity, operated by bariatric surgery, with good result, suffers a ventricular no supported polymorphic tachycardia while he was heightening treatment with aripiprazole and fluoxetine. CONCLUSIONS: To value the influence of diverse factors for the production of ventricular arrhythmias emphasizing fundamentally the interactions of aripiprazole and the loss of weight.

Oseltamivir- related psychiatric manifestations.

The importance effect on the population of the new virus Influenza A/H1N1 and the potential therapeutic with Oseltamivir. Clinical case. Patient of 62 years old, without history of interest, contracted Influeza A, that she undergoes a confusional syndrome responding to antipsychotics and with complete recovery after the episode. Conclusions. Establish the possible relationship between the various factors are influencing the onset confusional syndrome in a patient infected with Inluenza A treated with Oseltamivir.

Manifestaciones psiquiátricas relacionadas con oseltamivir / Oseltamivir-related psychiatric manifestations

Destacar la afectación en la población del nuevo virus Influenza A/H1N1 y la posibilidad terapéutica con oseltamivir. Caso clínico. Paciente de 62 años, sin antecedentes de interés, que contrajo la Gripe A, sufre un Síndrome confusional, que responde a antipsicóticos y con recuperación completa tras el episodio. Conclusiones. Establecer la posible relación entre los diversos factores que influyen en la aparición de un síndrome confusional en un paciente infectado con la gripe A que recibe tratamiento con Oseltamivir (AU)

The involvement of the new Influenza A/H1N1 virus and the treatment potential with Oseltamivir in the populationis stressed. Clinical case. A 62-year old patient, with no history of interest, who contracted Influenza A, suffered a confusional syndrome that responded to antipsychotics, with complete recovery after the episode. Conclusions. To establish the possible relationship between the various factors that affect the onset of a confusional syndrome in a patient infected with Influenza A treated with Oseltamivir (AU)

[Intracranial sinus thrombosis secondary to the consumption of inhaled speed]. / Trombosis de seno venoso intracraneal secundaria al consumo de speed inhalado.

INTRODUCTION: Speed is a psychostimulant of the Central Nervous System that can cause behavioral alterations, euphoria, psychosis and diverse organic medical pictures. CLINICAL CASE: The case of a 19 year old male patient, who consumes amphetamines, who had behavioral alterations and heteroaggressiveness, circumstances that required psychiatric admission is presented. After performing brain imaging tests, intracranial venous sinus thrombosis was found, which has not, up to the present date, developed significant symptoms. CONCLUSIONS: The aim of the above-mentioned report is to know the mechanism of action of the speed and to relate it consumption to the appearance of intracranial sinus thrombosis. To do so, a search was conducted in the PubMed database using the following terms: amphetamines and intracranial sinus thrombosis; street drugs and cerebrovascular disease; and adverse effects of the drugs.

Trombosis de seno venoso intracraneal secundaria al consumo de speed inhalado / Intracranial sinus thrombosis secondary to the consumption of inhaled speed

Introducción. El speed es un psicoestimulante del SNC que puede provocar alteraciones conductuales, euforia, psicosis y diversos cuadros a nivel orgánico. Caso clínico. Paciente de 19 años, consumidora de anfetaminas, que presentó alteraciones conductuales y heteroagresividad, circunstancias que requirieron ingreso psiquiátrico, en el cual tras la realización de pruebas de imagen cerebral se encontró una trombosis del seno venoso intracraneal que no había desarrollado sintomatología significativa hasta el momento. Conclusiones. El objetivo de dicha comunicación es conocer el mecanismo de acción del speed y relacionar su consumo con la aparición de trombosis del seno venoso. Para ello se ha realizado una búsqueda en la base de datos Pub-Med con los siguientes términos: amphetamines y thrombosissinus intracranial; street drugs y cerebrovascular disease;y adverse effects de las drogas (AU)

Introduction. Speed is a psychostimulant of the Central Nervous System that can cause behavioral alterations, euphoria, psychosis and diverse organic medical pictures. Clinical case. The case of a 19 year old male patient, who consumes amphetamines, who had behavioral alterations and hetero aggressiveness, circumstances that required psychiatric admission is presented. After performing brain imaging tests, intracranial venous sinus thrombosis was found, which has not, up to the present date, developed significant symptoms. Conclusions. The aim of the above-mentioned report is to know the mechanism of action of the speed and to relate it consumption to the appearance of intracranial sinus thrombosis. To do so, a search was conducted in the PubMed database using the following terms: amphetamines and intracranial sinus thrombosis; street drugs and cerebrovascular disease; and adverse effects of the drugs (AU)